Supplementary Table S4 from Safety Profile and Adverse Event Management for Futibatinib, An Irreversible FGFR1–4 Inhibitor: Pooled Safety Analysis of 469 Patients

crossref(2024)

引用 0|浏览4
暂无评分
摘要

Study drug exposure (overall and 20 mg QD)

更多
查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要